Biogen rises after 2nd-quarter results surpass forecasts


Biogen stock climbed Thursday after the drugmaker reported strong sales of some of its newest treatments for multiple sclerosis and hemophilia. The Cambridge, Massachusetts-based company's net income and sales were both stronger than investors expected.



from Biotech News